

**SEARCH REQUEST FORM**

Scientific and Technical Information Center

Requester's Full Name: \_\_\_\_\_ Examiner #: \_\_\_\_\_ Date: \_\_\_\_\_  
 Art Unit: \_\_\_\_\_ Phone Number 30 \_\_\_\_\_ Serial Number: \_\_\_\_\_  
 Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Point of Contact:  
 Toby Port  
 Technical Info. Specialist  
 CM1 6A04  
 703-308-3534

**STAFF USE ONLY**

	Type of Search	Vendors and cost where applicable
Searcher: _____	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>7/1</u>	Bibliographic <u>7</u>	Dr.Link _____
Date Completed: <u>7/1</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>1.5</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>1.5</u>	Other _____	Other (specify) _____

HOME | PDR | MULTI-DRUG | SEARCH | STEDMAN'S | HELP | FEEDBACK | PDR ADDENDA | HERBALS

▶ **STEDMAN'S** *The Best Words In Medicine.™*

PDR Electronic Library™

**Stedman's Medical Dictionary 27th Edition****apnea**

Absence of breathing. [G. *apnoia*, want of breath] **central apnea** a. as the result of medullary depression which inhibits respiratory movement. **deglutition apnea** inhibition of breathing during swallowing. **induced apnea** intentional respiratory arrest during general anesthesia produced by hypocapnia, a muscle relaxant drug, respiratory center depression, or sudden cessation of controlled respiration. **obstructive sleep apnea** a disorder, first described in 1965, characterized by recurrent interruptions of breathing during sleep due to temporary obstruction of the airway by lax, excessively bulky, or malformed pharyngeal tissues (soft palate, uvula, and sometimes tonsils), with resultant hypoxemia and chronic lethargy. Symptoms of obstructive sleep apnea are loud snoring, recurrent apneic episodes during sleep followed by gasping inspiration with partial or complete arousal, nocturnal restlessness, and daytime sleepiness. Apneic episodes last 10–120 seconds and may be accompanied by sinus bradycardia or atrioventricular block. The cumulative effect of recurrent spells of apnea is hypoxemia and shallow, nonrefreshing sleep, which may lead to excessive drowsiness, personality change, impairment of intellectual function, and heightened tendency to accidents during waking hours. However, evidence establishing obstructive sleep apnea as an independent risk factor for motor vehicle accidents, heart attack, stroke, and sudden death is weak. About 15% of persons with this disorder develop sustained pulmonary hypertension. Obstructive sleep apnea affects about 4% of men and 2% percent of women between the ages of 30 and 60. Obesity, hypothyroidism, cigarette smoking, alcohol, and some hypnotics (particularly benzodiazepines) predispose to this disorder, and its incidence increases with advancing age. Diagnosis is confirmed by polysomnography (continuous measurement of airflow, respiratory activity, chin electromyography, ECG, EEG, electrooculogram, and arterial oxygen saturation during sleep) and by evaluation of the shape and size of the upper respiratory tract. Weight loss, smoking cessation, and avoidance of benzodiazepine hypnotics are advised for all patients. A mandibular advancement appliance worn inside the mouth at night reduces symptoms in some patients. An effective if somewhat cumbrous treatment is the nightly use of continuous positive airway pressure, which provides a steady flow of room air at low pressure through the nose to overcome intermittent upper respiratory obstruction. Selected patients benefit from surgical procedures such as uvulopalatopharyngoplasty (trimming and reshaping of the uvula and soft palate), which can be performed by laser or radiofrequency ablation under local anesthesia, and mandibular osteotomy with genioglossus muscle advancement. **sleep apnea** central and/or peripheral a. during sleep, associated with frequent awakening and often with daytime sleepiness. Cf.: sleep-induced apnea. **sleep-induced apnea** a. resulting from failure of the respiratory center to stimulate adequate respiration during sleep; divided into respiratory pause (cessation of air flow for less than 10 seconds) and apneic pause (cessation of air flow greater than 10 seconds).

Copyright© 2000 Lippincott Williams &amp; Wilkins. All rights reserved.

Copyright © 2002 by Medical Economics Company, Inc. at Montvale, NJ 07645. All rights reserved.  
 Monographs from the 2002 Physicians Desk Reference  
[Click here to read our Warranty and Disclaimer.](#)

# National Library of Medicine - Medical Subject Headings

2002 MeSH

## MeSH Descriptor Data

[Return to Entry Page](#)

MeSH Heading	Apnea
Tree Number	C08.618.085
Tree Number	C23.888.852.130
Annotation	do not confuse APNEA with other resp disord: use only when text uses <u>APNEA</u> ; apnea neonatorum = <u>APNEA</u> + check tags <u>INFANT</u> , <u>NEWBORN</u> + <u>HUMAN</u>
Scope Note	A transient absence of spontaneous respiration.
Allowable Qualifiers	BL CF CI CL CN CO DH DI DT EC EH EM EN EP ET GE HI IM ME MI MO NU PA PC PP PS PX RA RH RI RT SU TH UR US VE VI
Unique ID	D001049

## MeSH Tree Structures

[Respiratory Tract Diseases \[C08\]](#)
[Respiration Disorders \[C08.618\]](#)

 ► [Apnea \[C08.618.085\]](#)

     [Sleep Apnea Syndromes \[C08.618.085.852\] +](#)

     [Cheyne-Stokes Respiration \[C08.618.182\]](#)

     [Cough \[C08.618.248\]](#)

     [Dyspnea \[C08.618.326\] +](#)

     [Hoarseness \[C08.618.490\]](#)

     [Hyperventilation \[C08.618.501\] +](#)

     [Laryngismus \[C08.618.573\]](#)

     [Meconium Aspiration \[C08.618.580\]](#)

     [Mouth Breathing \[C08.618.659\]](#)

     [Respiratory Distress Syndrome \[C08.618.801\] +](#)

     [Respiratory Distress Syndrome, Adult \[C08.618.840\]](#)

     [Respiratory Insufficiency \[C08.618.846\] +](#)

=> file reg

FILE 'REGISTRY' ENTERED AT 15:49:07 ON 09 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4  
DICTIONARY FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN 83863-69-8 REGISTRY  
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3R,4S)-3-methoxy-4-piperidinyl]-  
, rel- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)-, cis-  
OTHER NAMES:  
CN **Norcisapride**  
FS STEREOSEARCH  
DR 86718-38-9  
MF C14 H20 Cl N3 O3  
SR Commission of European Communities  
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, CHEMLIST, CIN, DRUGUPDATES,  
PHAR, TOXCENTER, USPAT2, USPATFULL  
Other Sources: EINECS\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

25 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
25 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d ide

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN 186260-03-7 REGISTRY  
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3R,4S)-3-methoxy-4-piperidinyl]-  
(9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)-,  
cis-(-)-  
OTHER NAMES:  
CN (-)-Norcisapride  
FS STEREOSEARCH  
MF C14 H20 Cl N3 O3  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP'.FORMAT\*\*

8 REFERENCES IN FILE CA (1967 TO DATE)  
8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file caplus; d que 114; d que 116; d que 126  
FILE 'CAPLUS' ENTERED AT 16:28:58 ON 09 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Jul 2002 VOL 137 ISS 2  
FILE LAST UPDATED: 8 Jul 2002 (20020708/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
L1      1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NORCISAPRIDE/CN
L2      28 SEA FILE=CAPLUS ABB=ON  PLU=ON  L1
L5      1879 SEA FILE=CAPLUS ABB=ON  PLU=ON  APNEA
L10     1 SEA FILE=REGISTRY ABB=ON  PLU=ON  186260-03-7/RN
L11     31 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2 OR L10
L12     27 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?NORCISAPRID?
L13     36 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11 OR L12
L14     2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13 AND L5
```

```
L1      1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NORCISAPRIDE/CN
L2      28 SEA FILE=CAPLUS ABB=ON  PLU=ON  L1
L10     1 SEA FILE=REGISTRY ABB=ON  PLU=ON  186260-03-7/RN
L11     31 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2 OR L10
L12     27 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?NORCISAPRID?
L13     36 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11 OR L12
L15     25887 SEA FILE=CAPLUS ABB=ON  PLU=ON  BREATH?
L16     0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13 AND L15
```

```
L1      1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NORCISAPRIDE/CN
L2      28 SEA FILE=CAPLUS ABB=ON  PLU=ON  L1
L10     1 SEA FILE=REGISTRY ABB=ON  PLU=ON  186260-03-7/RN
L11     31 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2 OR L10
L12     27 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?NORCISAPRID?
L13     36 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11 OR L12
L22     151284 SEA FILE=CAPLUS ABB=ON  PLU=ON  RESPIRAT?
L23     144764 SEA FILE=CAPLUS ABB=ON  PLU=ON  LUNG
L24     33525 SEA FILE=CAPLUS ABB=ON  PLU=ON  DIAPHRAGM
L25     542578 SEA FILE=CAPLUS ABB=ON  PLU=ON  OXYGEN
L26     2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13 AND (L22 OR L23 OR L24 OR
      L25)
```

```
=> s l14 or l16 or l26
L53      4 L14 OR L16 OR L26
```

```
=> file medline; d que 120; d que 121; d que 132
FILE 'MEDLINE' ENTERED AT 16:29:37 ON 09 JUL 2002
```

FILE LAST UPDATED: 7 JUL 2002 (20020707/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

```
L17      5 SEA FILE=MEDLINE ABB=ON  PLU=ON  NORCISAPRIDE/CN
L18     15778 SEA FILE=MEDLINE ABB=ON  PLU=ON  APNEA
```

L20 0 SEA FILE=MEDLINE ABB=ON PLU=ON L17 AND L18

L17 5 SEA FILE=MEDLINE ABB=ON PLU=ON NORCISAPRIDE/CN

L19 47588 SEA FILE=MEDLINE ABB=ON PLU=ON BREATH?

L21 0 SEA FILE=MEDLINE ABB=ON PLU=ON L17 AND L19

L17 5 SEA FILE=MEDLINE ABB=ON PLU=ON NORCISAPRIDE/CN

L27 55992 SEA FILE=MEDLINE ABB=ON PLU=ON RESPIRATORY MECHANICS+NT/CT

L28 51115 SEA FILE=MEDLINE ABB=ON PLU=ON RESPIRATION/CT

L29 68074 SEA FILE=MEDLINE ABB=ON PLU=ON OXYGEN CONSUMPTION/CT

L30 222261 SEA FILE=MEDLINE ABB=ON PLU=ON RESPIRATORY SYSTEM+NT/CT

L31 13880 SEA FILE=MEDLINE ABB=ON PLU=ON RESPIRATORY MUSCLES+NT/CT

L32 0 SEA FILE=MEDLINE ABB=ON PLU=ON L17 AND (L27 OR L28 OR L29 OR  
L30 OR L31)

=> file embase; d que 135

FILE 'EMBASE' ENTERED AT 16:29:45 ON 09 JUL 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 8 Jul 2002 (20020708/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

L33 9 SEA FILE=EMBASE ABB=ON PLU=ON NORCISAPRIDE/CT

L34 82047 SEA FILE=EMBASE ABB=ON PLU=ON RESPIRATORY FUNCTION DISORDER+N  
T/CT

L35 0 SEA FILE=EMBASE ABB=ON PLU=ON L33 AND L34

=> file biosis; d que 148

FILE 'BIOSIS' ENTERED AT 16:30:01 ON 09 JUL 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 3 July 2002 (20020703/ED)

L46 31 SEA FILE=BIOSIS ABB=ON PLU=ON NORCISAPRID?

L47 749378 SEA FILE=BIOSIS ABB=ON PLU=ON RESPIRAT? OR OXYGEN OR BREATH?  
OR LUNG OR DIAPHRAGM? OR APNEA?

L48 2 SEA FILE=BIOSIS ABB=ON PLU=ON L46 AND L47

=> file wpid; d que 143; d que 145; d que 150

FILE 'WPIDS' ENTERED AT 16:30:18 ON 09 JUL 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 04 JUL 2002

<20020704/UP>

MOST RECENT DERWENT UPDATE 200242 <200242/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> Update 2002-42 does not contain any new polymer indexing <<<

>>> The BATCH option for structure searches has been  
 enabled in WPINDEX/WPIDS and WPIX >>>

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY >>>

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,  
 SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
 PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
 GUIDES, PLEASE VISIT:  
[http://www.derwent.com/userguides/dwpi\\_guide.html](http://www.derwent.com/userguides/dwpi_guide.html) <<<

L36	9	SEA FILE=WPIDS	ABB=ON	PLU=ON	NORCISAPRID?
L38	14716	SEA FILE=WPIDS	ABB=ON	PLU=ON	BREATH?
L39	17215	SEA FILE=WPIDS	ABB=ON	PLU=ON	RESPIRAT?
L40	13422	SEA FILE=WPIDS	ABB=ON	PLU=ON	LUNG
L41	60992	SEA FILE=WPIDS	ABB=ON	PLU=ON	DIAPHRAGM?
L42	157661	SEA FILE=WPIDS	ABB=ON	PLU=ON	OXYGEN
L43	1	SEA FILE=WPIDS	ABB=ON	PLU=ON	L36 AND (L38 OR L39 OR L40 OR L41 OR L42)

L37	77	SEA FILE=WPIDS	ABB=ON	PLU=ON	CISAPRID?
L38	14716	SEA FILE=WPIDS	ABB=ON	PLU=ON	BREATH?
L39	17215	SEA FILE=WPIDS	ABB=ON	PLU=ON	RESPIRAT?
L40	13422	SEA FILE=WPIDS	ABB=ON	PLU=ON	LUNG
L41	60992	SEA FILE=WPIDS	ABB=ON	PLU=ON	DIAPHRAGM?
L42	157661	SEA FILE=WPIDS	ABB=ON	PLU=ON	OXYGEN
L44	6	SEA FILE=WPIDS	ABB=ON	PLU=ON	L37 AND (L38 OR L39 OR L40 OR L41 OR L42)
L45	1	SEA FILE=WPIDS	ABB=ON	PLU=ON	L44 AND OBSTRUC?/TI

L36	9	SEA FILE=WPIDS	ABB=ON	PLU=ON	NORCISAPRID?
L49	626	SEA FILE=WPIDS	ABB=ON	PLU=ON	APNEA
L50	2	SEA FILE=WPIDS	ABB=ON	PLU=ON	L36 AND L49

=> s 143 or 145 or 150

L54 3 L43 OR L45 OR L50

=> dup rem 153 154 148

PROCESSING COMPLETED FOR L53

PROCESSING COMPLETED FOR L54

PROCESSING COMPLETED FOR L48

L56 7 DUP REM L53 L54 L48 (2 DUPLICATES REMOVED)  
 ANSWERS '1-4' FROM FILE CAPLUS  
 ANSWERS '5-6' FROM FILE WPIDS  
 ANSWER '7' FROM FILE BIOSIS



=&gt; d ibib ab 156 1-7

L56 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1  
 ACCESSION NUMBER: 2000:238050 CAPLUS  
 DOCUMENT NUMBER: 132:260706  
 TITLE: Methods for treating **apnea, apnea**  
 disorders, bulimia, and other disorders using  
 optically pure (+)-**norcisapride**  
 INVENTOR(S): Rubin, Paul D.; Barberich, Timothy J.  
 PATENT ASSIGNEE(S): Sepracor Inc., USA  
 SOURCE: U.S., 9 pp., which  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6048879	A	20000411	US 1999-332196	19990614
WO 9965571	A2	19991223	WO 1999-US13099	19990610
WO 9965571	A3	20000420		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9911299	A	20010313	BR 1999-11299	19990610
EP 1089733	A2	20010411	EP 1999-927431	19990610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002518352	T2	20020625	JP 2000-554444	19990610
US 6369079	B1	20020409	US 2000-515390	20000229
NO 2000006357	A	20010213	NO 2000-6357	20001213
PRIORITY APPLN. INFO.:				
			US 1998-89224P	P 19980615
			US 1999-122275P	P 19990301
			WO 1999-US13099	W 19990610
			US 1999-332196	A3 19990614

AB Methods are provided for the prevention, treatment or management of **apnea, apnea** disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+)-**norcisapride**, or a pharmaceutically acceptable salt thereof, substantially free of its (-)-stereoisomer.

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
 ACCESSION NUMBER: 1999:811080 CAPLUS  
 DOCUMENT NUMBER: 132:45001  
 TITLE: Use of optically pure (-) **norcisapride** in the treatment of **apnea**, bulimia, and other disorders  
 INVENTOR(S): Rubin, Paul D.; Barberich, Timothy J.  
 PATENT ASSIGNEE(S): Sepracor, Inc., USA  
 SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965490	A2	19991223	WO 1999-US13100	19990610
WO 9965490	A3	20000413		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9946784	A1	20000105	AU 1999-46784	19990610
BR 9911302	A	20010313	BR 1999-11302	19990610
EP 1087765	A2	20010404	EP 1999-930196	19990610
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
NO 2000006358	A	20010213	NO 2000-6358	20001213
PRIORITY APPLN. INFO.:			US 1998-89225P P	19980615
			US 1999-122236P P	19990301
			WO 1999-US13100 W	19990610

AB Methods are provided for the prevention, treatment, or management of **apnea**, **apnea** disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof, using (-) **norcisapride**, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

L56 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:353274 CAPLUS  
 DOCUMENT NUMBER: 136:363862  
 TITLE: Composition comprising: serotonin receptor antagonists (5HT-2, 5HT-3) and agonist (5HT-4)  
 INVENTOR(S): Skogvall, Staffan  
 PATENT ASSIGNEE(S): Respiratorius A.B., Swed.  
 SOURCE: PCT Int. Appl., 160 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036113	A1	20020510	WO 2001-SE2372	20011030
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 PRIORITY APPLN. INFO.: SE 2000-3995 A 20001101  
 US 2000-244661P P 20001101

AB A compn. comprising a combination of (a) at least one compd. with agonist activity to the 5-HT4 receptor, (b) at least one compd. with antagonist activity to the 5-HT3 receptor, and (c) at least one compd. with antagonist activity to the 5-HT2 receptor is described. The invention relates to the use of said compn. as a medicament for therapeutic or prophylactic treatment of disorders involving airway constriction in humans or animals.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:923608 CAPLUS

DOCUMENT NUMBER: 136:31700

TITLE: A compn. comprising a combination of 5-HT4 receptor agonists and 5-HT3 receptor antagonists for treatment of disorders involving airway constriction

INVENTOR(S): Skogvall, Staffan

PATENT ASSIGNEE(S): Respiratorius AB, Swed.

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095902	A1	20011220	WO 2000-SE2612	20001220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: SE 2000-1267 A 20000615

AB The present invention relates to a compn. comprising a combination of (a) at least one compd. with agonist activity to the 5-HT4 receptor and (b) at least one compd. with antagonist activity to the 5-HT3 receptor and to the use of said compd. in the manuf. of a medicament for therapeutic or prophylactic treatment of disorders involving airway constriction of a human or animal body, as well as methods of treatment, wherein said compds. are administered.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 5 OF 7 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2002-106446 [14] WPIDS

CROSS REFERENCE: 2001-031656 [66]; 2002-074902 [28]; 2002-106445 [09]

DOC. NO. CPI: C2002-032753

TITLE: New serotonin 5-HT3 receptors used for treating disorders involving airway constriction e.g. asthma, chronic bronchitis and chronic obstructive pulmonary disorders.

DERWENT CLASS: B05

INVENTOR(S): SKOGVALL, S

PATENT ASSIGNEE(S): (RESP-N) RESPIRATORIUS AB

COUNTRY COUNT: 94  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001095903	A1	20011220	(200214)*	EN	112
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001025664	A	20011224	(200227)		

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001095903	A1	WO 2000-SE2613	20001220
AU 2001025664	A	AU 2001-25664	20001220

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001025664	A Based on	WO 200195903

PRIORITY APPLN. INFO: WO 2000-SE1267 20000615

AB WO 200195903 A UPAB: 20020429

NOVELTY - Serotonin (5-HT<sub>3</sub>) receptors (I), its derivatives or salts are used for treatment of disorders involving airway constriction.

ACTIVITY - **Respiratory**; Antiasthmatic; Antiinflammatory.

MECHANISM OF ACTION - 5-HT<sub>3</sub> receptor antagonist; 5-HT<sub>4</sub> receptor agonist.

Tests are described, but no results are given.

USE - Used for treatment and prophylaxis of disorders involving airway constriction, particularly asthma, emphysema, chronic bronchitis and chronic obstructive pulmonary diseases (claimed).

ADVANTAGE - The compound has the capacity of reducing pathological broncho-contraction by at least 30 (preferably at least 60, especially at least 90)%.

Dwg.0/1

L56 ANSWER 6 OF 7 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2000-160496 [14] WPIDS

DOC. NO. CPI: C2000-050053

TITLE: Treating e.g. bulimia, **apnea**, irritable bowel syndrome, bradycardia, bradyarrhythmia comprises administration of (+) **norcisapride**.

DERWENT CLASS: B03

INVENTOR(S): BARBERICH, T J; RUBIN, P D

PATENT ASSIGNEE(S): (SEPR-N) SEPRACOR INC

COUNTRY COUNT: 87

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9965571	A2	19991223	(200014)*	EN	30
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB					

GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU  
 LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR  
 TT UA UG UZ VN YU ZA ZW  
 AU 9944333 A 20000105 (200024)  
 US 6048879 A 20000411 (200025)  
 BR 9911299 A 20010313 (200118)  
 EP 1089733 A2 20010411 (200121) EN  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 NO 2000006357 A 20010213 (200123)  
 SK 2000001905 A3 20010611 (200157)  
 CZ 2000004737 A3 20011017 (200172)  
 KR 2001052739 A 20010625 (200173)  
 CN 1312717 A 20010912 (200202)  
 HU 2001002203 A2 20011128 (200209)  
 ZA 2000007258 A 20011224 (200212) 48  
 US 6369079 B1 20020409 (200227)  
 MX 2000012364 A1 20010801 (200238)  
 JP 2002518352 W 20020625 (200243) 42

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9965571	A2	WO 1999-US13099	19990610
AU 9944333	A	AU 1999-44333	19990610
US 6048879	A Provisional	US 1998-89224P	19980615
	Provisional	US 1999-122275P	19990301
		US 1999-332196	19990614
BR 9911299	A	BR 1999-11299	19990610
		WO 1999-US13099	19990610
EP 1089733	A2	EP 1999-927431	19990610
		WO 1999-US13099	19990610
NO 2000006357	A	WO 1999-US13099	19990610
		NO 2000-6357	20001213
SK 2000001905	A3	WO 1999-US13099	19990610
		SK 2000-1905	19990610
CZ 2000004737	A3	WO 1999-US13099	19990610
		CZ 2000-4737	19990610
KR 2001052739	A	KR 2000-714024	20001211
CN 1312717	A	CN 1999-809565	19990610
HU 2001002203	A2	WO 1999-US13099	19990610
		HU 2001-2203	19990610
ZA 2000007258	A	ZA 2000-7258	20001207
US 6369079	B1 Provisional	US 1998-89224P	19980615
	Provisional	US 1999-122275P	19990301
	Div ex	US 1999-332196	19990614
		US 2000-515390	20000229
MX 2000012364	A1	MX 2000-12364	20001213
JP 2002518352	W	WO 1999-US13099	19990610
		JP 2000-554444	19990610

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9944333	A Based on	WO 9965571
BR 9911299	A Based on	WO 9965571
EP 1089733	A2 Based on	WO 9965571
SK 2000001905	A3 Based on	WO 9965571
CZ 2000004737	A3 Based on	WO 9965571

HU 2001002203 A2 Based on WO 9965571  
US 6369079 B1 Div ex US 6048879  
JP 2002518352 W Based on WO 9965571

PRIORITY APPLN. INFO: US 1999-122275P 19990301; US 1998-89224P  
19980615; US 1999-332196 19990614; US  
2000-515390 20000229

AB WO 9965571 A UPAB: 20000320

NOVELTY - Treating bulimia, disorders mediated by vagal activity, irritable bowel syndrome, bradycardia or bradyarrhythmia, asthma, urinary incontinence, **apnea** or **apnea** disorders comprises administration of (+)**norcisapride** or its salts, free of its (-)-stereoisomer.

ACTIVITY - Eating-Disorders-Gen.; CNS-Gen; gastrointestinal-Gen; cardiant; antiarrhythmic; antiasthmatic; uropathic; **respiratory** Gen.

MECHANISM OF ACTION - Serotonergic.

(+)**Norcisapride** exhibited IC50 values of 0.0054 and 0.38  $\mu$  M at 5-HT1A and 5-HT2 receptors, respectively. In comparison, ( plus or minus ) **norcisapride** displayed IC50 values of 7.48 and 2.21  $\mu$  M at these receptors, respectively.

USE - (+)**Norcisapride** can be used for treating bulimia, **apnea** (e.g. central **apnea**, deglutition **apnea**, obstructive **apnea**, sleep **apnea** or sleep induced **apnea**), irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, and syncope.

ADVANTAGE - The use of (+)**norcisapride** avoids the adverse side effects associated with administration of racemic **cisapride**.  
Dwg.0/0

L56 ANSWER 7 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:282909 BIOSIS

DOCUMENT NUMBER: PREV200200282909

TITLE: Methods for treating irritable bowel syndrome using optically pure (+) **norcisapride**.

AUTHOR(S): Rubin, Paul D.; Barberich, Timothy J.  
ASSIGNEE: Sepracor, Inc.

PATENT INFORMATION: US 6369079 April 09, 2002

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 9, 2002) Vol. 1257, No. 2, pp. No  
Pagination. <http://www.uspto.gov/web/menu/patdata.html>.  
e-file.  
ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

AB Methods for the prevention, treatment, or management of **apnea**, **apnea** disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) **norcisapride**, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

=> file home

FILE 'HOME' ENTERED AT 16:35:15 ON 09 JUL 2002